Patrick Trucchio
Recent Articles about Altimmune Inc.
Biopharma's New MASH Drug Has Two MOAs 10/15/2025
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
